A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Status: Recruiting
Phase:
Diagnosis: GYN: Endometrial/Uterine Cancer
NCT ID: NCT01420081
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-399
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
Conducting Institutions:
Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute
Overall PI:
Michael Birrer, MD, PhD,
Massachusetts General Hospital
Site-responsible Investigators:
Andrea Myers, MD,
Dana Farber Cancer Institute
Contacts:
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute:
Christin Whalen, 617-582-7738,
cwhalen@partners.org
Eligibility Criteria
Inclusion Criteria:
- Recurrent endometrial carcinoma
- Disease progression following one or two lines of prior treatment with platinum
containing chemotherapy
- Tumor tissue available at time of screening for PI3K analysis
- Adequate performance status
- Adequate glucose control, bone marrow, kidney, liver, and heart function
Exclusion Criteria:
- More than 2 prior cytotoxic chemo regimens for endometrial carcinoma
- Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor
- Active brain metastases